Thomas R. Hickey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thomas R. Hickey has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Joao Paulo de Aquino Lima
Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States
3 shared publications - Victor Javier Avila-Quintero
Child Study Center, Yale University School of Medicine, New Haven, Connecticut, USA
3 shared publications Gabriel P A Costa
Universidade de Ribeirão Preto, Ribeirão Preto, SP, Brazil
2 shared publicationsAlbert C Perrino
Anesthesiology, Yale School of Medicine, New Haven, Connecticut, USA
1 shared publicationAlexandra Podosek
Pharmacy, VA Connecticut Healthcare System, West Haven, Connecticut, USA
1 shared publicationAndres Missair
Bruce W Carter Department of Veterans Affairs Medical Center, Miami, Florida, USA
1 shared publication
Latest Publications
- 18 February 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Buprenorphine: a “win-win” for acute postoperative pain
- 18 February 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Buprenorphine: a “win-win” for acute postoperative pain
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 29-35
The past is prologue: Reconceptualizing methadone and buprenorphine for post-operative pain
Opioids remain a central element of perioperative pain management despite increased utilization of multimodal adjuvant strategies intended to reduce their use. Contemporary use of methadone and buprenorphine, both conceived as opioid analgesics, is dominated by their essential roles in the treatment of opioid use disorder. Compared to usual care opioids, however, they provide improved post-operative pain control while reducing analgesic requirements. These findings argue for their expanded role within perioperative multimodal analgesia strategies.
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 29-35
The past is prologue: Reconceptualizing methadone and buprenorphine for post-operative pain
Opioids remain a central element of perioperative pain management despite increased utilization of multimodal adjuvant strategies intended to reduce their use. Contemporary use of methadone and buprenorphine, both conceived as opioid analgesics, is dominated by their essential roles in the treatment of opioid use disorder. Compared to usual care opioids, however, they provide improved post-operative pain control while reducing analgesic requirements. These findings argue for their expanded role within perioperative multimodal analgesia strategies.
- 7 July 2025
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 39 (4) , 555-566
Establishing Buprenorphine for Acute Postoperative Pain Management
Opioids continue to be relied on to treat postoperative pain and continue to result in harms ranging from pruritis to overdose. The partial agonist opioid buprenorphine was synthesized in the 1960s as result of a search for a safe and effective opioid analgesic. While formulations of buprenorphine are approved for the treatment of pain, it is more commonly known as a medication for opioid use disorder. However, there is increasing interest in employing buprenorphine as a front-line perioperative opioid analgesic. We review the continued reliance on full agonist opioids and associated harms, highlight key efficacy and safety advantages of buprenorphine compared to usual care opioids, and describe the evolution of our consideration of buprenorphine for acute perioperative pain management. We then describe the process by which we worked within our institution to arrive at a twice daily buccal film and describe the clinical pathway ultimately implemented, providing details on training of staff, order set development, and surgical populations included. Buprenorphine presents a promising opportunity to reduce opioid harms while potentially improving pain outcomes after surgery. Our experience suggests that the buccal formulation possesses unique advantages for perioperative administration. Future directions will inform buprenorphine's impact on key pain and opioid-related outcomes.
- 7 July 2025
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 39 (4) , 555-566
Establishing Buprenorphine for Acute Postoperative Pain Management
Opioids continue to be relied on to treat postoperative pain and continue to result in harms ranging from pruritis to overdose. The partial agonist opioid buprenorphine was synthesized in the 1960s as result of a search for a safe and effective opioid analgesic. While formulations of buprenorphine are approved for the treatment of pain, it is more commonly known as a medication for opioid use disorder. However, there is increasing interest in employing buprenorphine as a front-line perioperative opioid analgesic. We review the continued reliance on full agonist opioids and associated harms, highlight key efficacy and safety advantages of buprenorphine compared to usual care opioids, and describe the evolution of our consideration of buprenorphine for acute perioperative pain management. We then describe the process by which we worked within our institution to arrive at a twice daily buccal film and describe the clinical pathway ultimately implemented, providing details on training of staff, order set development, and surgical populations included. Buprenorphine presents a promising opportunity to reduce opioid harms while potentially improving pain outcomes after surgery. Our experience suggests that the buccal formulation possesses unique advantages for perioperative administration. Future directions will inform buprenorphine's impact on key pain and opioid-related outcomes.
- 17 May 2025
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 26 (9) , 1041-1054
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder
A critical challenge in providing effective medical care for individuals in opioid agonist treatment (OAT) for opioid use disorder is the effective management of acute and chronic pain. While pain commonly co-occurs with opioid use disorder, there is limited research to guide effective management of pain in this population. We first provide an overview of the etiology and treatment of acute and chronic pain, highlighting areas of complexity for patients receiving OAT. We then describe the search strategy, which involved a date-inclusive search for relevant terms in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. After summarizing the results of this search on the evidence for pharmacological and behavioral treatments of acute and chronic pain for individuals on OAT, we conclude with a discussion of these finding and a summarized expert opinion on the state of the evidence. The evidence suggests that while research on effective treatment of acute and chronic pain in individuals in OAT is limited, promising work is ongoing to translate existing treatments, particularly behavioral treatments for chronic pain, to support this population. However, further research is warranted, particularly regarding pharmacological options.
- 17 May 2025
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 26 (9) , 1041-1054
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder
A critical challenge in providing effective medical care for individuals in opioid agonist treatment (OAT) for opioid use disorder is the effective management of acute and chronic pain. While pain commonly co-occurs with opioid use disorder, there is limited research to guide effective management of pain in this population. We first provide an overview of the etiology and treatment of acute and chronic pain, highlighting areas of complexity for patients receiving OAT. We then describe the search strategy, which involved a date-inclusive search for relevant terms in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. After summarizing the results of this search on the evidence for pharmacological and behavioral treatments of acute and chronic pain for individuals on OAT, we conclude with a discussion of these finding and a summarized expert opinion on the state of the evidence. The evidence suggests that while research on effective treatment of acute and chronic pain in individuals in OAT is limited, promising work is ongoing to translate existing treatments, particularly behavioral treatments for chronic pain, to support this population. However, further research is warranted, particularly regarding pharmacological options.
- 10 February 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (10) , 1230
Response to the letter to the editor
- 10 February 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (10) , 1230
Response to the letter to the editor
- Open Access
- 9 January 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (5) , 594-595
Buprenorphine versus full agonist opioids for acute postoperative pain management: an infographic
Opioids continue to play a role in postoperative pain management and continue to result in predictable harm to patients including persistent use and overdose.1 Buprenorphine, a partial agonist opioid, has an almost 60-year track record of efficacy in acute pain management. However, in contemporary practice, it is rarely used for this purpose and is better known as an essential medicine for opioid use disorder. In this systematic review and meta-analysis of randomized controlled trials, the authors aimed to broaden the understanding of buprenorphine’s efficacy versus opioids as a class in the treatment of acute postoperative pain in adults. Inclusion criteria were met for 58 studies.
- 9 January 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (5) , 594-595
Open AccessBuprenorphine versus full agonist opioids for acute postoperative pain management: an infographic
Opioids continue to play a role in postoperative pain management and continue to result in predictable harm to patients including persistent use and overdose.1 Buprenorphine, a partial agonist opioid, has an almost 60-year track record of efficacy in acute pain management. However, in contemporary practice, it is rarely used for this purpose and is better known as an essential medicine for opioid use disorder. In this systematic review and meta-analysis of randomized controlled trials, the authors aimed to broaden the understanding of buprenorphine’s efficacy versus opioids as a class in the treatment of acute postoperative pain in adults. Inclusion criteria were met for 58 studies.
- Top Cited Papers
- 2 January 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (1) , 1-16
Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials
Background/Importance: Opioids continue to play a key role in managing acute postoperative pain, but their use contributes to adverse outcomes. Buprenorphine may offer effective analgesia with a superior safety profile. Objective: To compare the efficacy and safety of buprenorphine with other opioids for acute postoperative pain management in adults. Evidence review: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched from inception to February 2024. Randomized controlled trials comparing buprenorphine with other opioids for acute postoperative pain management in adults were included. Of 2421 records identified, 58 studies met inclusion criteria. Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analysis was performed using Stata/BE V.18. The primary outcome was pain intensity. Secondary outcomes included rescue analgesia use, duration of analgesia, and adverse effects. Findings: Analysis of 41 comparisons (2587 participants) showed buprenorphine significantly reduced pain intensity compared with all other opioids (Hedges’s g=−0.36, 95% CI=−0.59 to −0.14, p2 =86.28%, 95% CI=81.55% to 88.99%) and moderate for rescue analgesia (I 2 =38.93%, 95% CI=1.44% to 64.37%). Risk of bias was low in 19 studies, with some concerns in 37 studies, and high in two studies. Conclusions: Buprenorphine demonstrated superior efficacy in managing acute postoperative pain compared with FAOs, with a favorable safety profile and longer duration of action. These findings support the use of buprenorphine as a first-line opioid analgesic for acute postoperative pain management requiring opioid analgesia, potentially reducing opioid-related harm in the postoperative period. PROSPERO registration number: CRD42023447715.
- 2 January 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (1) , 1-16
Top Cited PapersBuprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials
Background/Importance: Opioids continue to play a key role in managing acute postoperative pain, but their use contributes to adverse outcomes. Buprenorphine may offer effective analgesia with a superior safety profile. Objective: To compare the efficacy and safety of buprenorphine with other opioids for acute postoperative pain management in adults. Evidence review: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched from inception to February 2024. Randomized controlled trials comparing buprenorphine with other opioids for acute postoperative pain management in adults were included. Of 2421 records identified, 58 studies met inclusion criteria. Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analysis was performed using Stata/BE V.18. The primary outcome was pain intensity. Secondary outcomes included rescue analgesia use, duration of analgesia, and adverse effects. Findings: Analysis of 41 comparisons (2587 participants) showed buprenorphine significantly reduced pain intensity compared with all other opioids (Hedges’s g=−0.36, 95% CI=−0.59 to −0.14, p2 =86.28%, 95% CI=81.55% to 88.99%) and moderate for rescue analgesia (I 2 =38.93%, 95% CI=1.44% to 64.37%). Risk of bias was low in 19 studies, with some concerns in 37 studies, and high in two studies. Conclusions: Buprenorphine demonstrated superior efficacy in managing acute postoperative pain compared with FAOs, with a favorable safety profile and longer duration of action. These findings support the use of buprenorphine as a first-line opioid analgesic for acute postoperative pain management requiring opioid analgesia, potentially reducing opioid-related harm in the postoperative period. PROSPERO registration number: CRD42023447715.
- 1 December 2024
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 20 (6) , 503-527
Buprenorphine: An anesthesia-centric review
Buprenorphine was synthesized in the 1960s as a result of a search for a safe and effective opioid analgesic. Present formulations of buprenorphine are approved for the treatment of both acute and chronic pain. Its long duration of action, high affinity, and partial agonism at the μ-opioid receptor have established it as a mainstay treatment for opioid use disorder (OUD). Full agonist opioids (FAOs) remain a primary choice for perioperative pain in both opioid-naïve and opioid-tolerant patients despite well-known harms and new emphasis on multimodal analgesia strategies prioritizing nonopioid analgesics. We review the evidence supporting the use of buprenorphine as an effective analgesic alternative to more commonly prescribed FAOs in acute and chronic pain management. For the patient prescribed buprenorphine for OUD, prior conventionalism advised temporary discontinuation of buprenorphine preoperatively; this paradigm has shifted toward continuing buprenorphine throughout the perioperative period. Questions remain whether dose adjustments may improve patient outcomes.
- 1 December 2024
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 20 (6) , 503-527
Buprenorphine: An anesthesia-centric review
Buprenorphine was synthesized in the 1960s as a result of a search for a safe and effective opioid analgesic. Present formulations of buprenorphine are approved for the treatment of both acute and chronic pain. Its long duration of action, high affinity, and partial agonism at the μ-opioid receptor have established it as a mainstay treatment for opioid use disorder (OUD). Full agonist opioids (FAOs) remain a primary choice for perioperative pain in both opioid-naïve and opioid-tolerant patients despite well-known harms and new emphasis on multimodal analgesia strategies prioritizing nonopioid analgesics. We review the evidence supporting the use of buprenorphine as an effective analgesic alternative to more commonly prescribed FAOs in acute and chronic pain management. For the patient prescribed buprenorphine for OUD, prior conventionalism advised temporary discontinuation of buprenorphine preoperatively; this paradigm has shifted toward continuing buprenorphine throughout the perioperative period. Questions remain whether dose adjustments may improve patient outcomes.